BACKGROUND DATA: The REMATCH trial evaluated the efficacy and safety of long-term left ventricular assist device (LVAD) support in stage D chronic end-stage heart failure patients. Compared with optimal medical management, LVAD implantation significantly improved the survival and quality of life of these terminally ill patients. To date, however, there have been no analyses of the cost related to the LVAD survival benefit. This paper addresses the cost of hospital resource use, and its predictors, for long-term LVAD patients. METHODS: Detailed cost data were available for 52 of 68 REMATCH patients randomized to LVAD therapy. We combined the clinical dataset with Medicare data, standard billing forms (UB-92), and line item bills provided directly by clinical centers. Charges were converted to costs by using the Ratio-of-Cost-to-Charges for each major resource category. RESULTS: The mean cost for the initial implant-related hospitalization was $210,187 +/- 193,295. When implantation hospitalization costs are compared between hospital survivors and nonsurvivors, the mean costs increase from $159,271 +/- 106,423 to $315,015 +/- 278,713. Sepsis, pump housing infection, and perioperative bleeding are the major drivers of implantation cost, established by regression modeling. In the patients who survived the procedure (n = 35), bypass time, perioperative bleeding, and late bleeding were the drivers of cost. The average annual readmission cost per patient for the overall cohort was $105,326. CONCLUSIONS: The cost of long-term LVAD implantation is commensurate with other life-saving organ transplantation procedures like liver transplantation. As an evolving technology, there are a number of opportunities for improvement that will likely reduce costs in the future.
RCT Entities:
BACKGROUND DATA: The REMATCH trial evaluated the efficacy and safety of long-term left ventricular assist device (LVAD) support in stage D chronic end-stage heart failurepatients. Compared with optimal medical management, LVAD implantation significantly improved the survival and quality of life of these terminally ill patients. To date, however, there have been no analyses of the cost related to the LVAD survival benefit. This paper addresses the cost of hospital resource use, and its predictors, for long-term LVADpatients. METHODS: Detailed cost data were available for 52 of 68 REMATCH patients randomized to LVAD therapy. We combined the clinical dataset with Medicare data, standard billing forms (UB-92), and line item bills provided directly by clinical centers. Charges were converted to costs by using the Ratio-of-Cost-to-Charges for each major resource category. RESULTS: The mean cost for the initial implant-related hospitalization was $210,187 +/- 193,295. When implantation hospitalization costs are compared between hospital survivors and nonsurvivors, the mean costs increase from $159,271 +/- 106,423 to $315,015 +/- 278,713. Sepsis, pump housing infection, and perioperative bleeding are the major drivers of implantation cost, established by regression modeling. In the patients who survived the procedure (n = 35), bypass time, perioperative bleeding, and late bleeding were the drivers of cost. The average annual readmission cost per patient for the overall cohort was $105,326. CONCLUSIONS: The cost of long-term LVAD implantation is commensurate with other life-saving organ transplantation procedures like liver transplantation. As an evolving technology, there are a number of opportunities for improvement that will likely reduce costs in the future.
Authors: E A Rose; A C Gelijns; A J Moskowitz; D F Heitjan; L W Stevenson; W Dembitsky; J W Long; D D Ascheim; A R Tierney; R G Levitan; J T Watson; P Meier; N S Ronan; P A Shapiro; R M Lazar; L W Miller; L Gupta; O H Frazier; P Desvigne-Nickens; M C Oz; V L Poirier Journal: N Engl J Med Date: 2001-11-15 Impact factor: 91.245
Authors: M C Deng; M Loebe; A El-Banayosy; E Gronda; P G Jansen; M Vigano; G M Wieselthaler; B Reichart; E Vitali; A Pavie; T Mesana; D Y Loisance; D R Wheeldon; P M Portner Journal: Circulation Date: 2001-01-16 Impact factor: 29.690
Authors: R M Califf; K F Adams; W J McKenna; M Gheorghiade; B F Uretsky; S E McNulty; H Darius; K Schulman; F Zannad; E Handberg-Thurmond; F E Harrell; W Wheeler; J Soler-Soler; K Swedberg Journal: Am Heart J Date: 1997-07 Impact factor: 4.749
Authors: M C Oz; D J Goldstein; P Pepino; A D Weinberg; S M Thompson; K A Catanese; R L Vargo; P M McCarthy; E A Rose; H R Levin Journal: Circulation Date: 1995-11-01 Impact factor: 29.690
Authors: Biswajit Kar; Lindsay E Adkins; Andrew B Civitello; Pranav Loyalka; Nanthini Palanichamy; Courtney J Gemmato; Timothy J Myers; Igor D Gregoric; Reynolds M Delgado Journal: Tex Heart Inst J Date: 2006
Authors: Thomas Puehler; Stephan Ensminger; Michael Schoenbrodt; Jochen Börgermann; Erik Rehn; Kavous Hakim-Meibodi; Michiel Morshuis; Jan Gummert Journal: Ann Cardiothorac Surg Date: 2014-09
Authors: Daniel P Mulloy; Castigliano M Bhamidipati; Matthew L Stone; Gorav Ailawadi; Irving L Kron; John A Kern Journal: J Thorac Cardiovasc Surg Date: 2012-12-13 Impact factor: 5.209
Authors: Jeremiah G Allen; Eric S Weiss; Justin M Schaffer; Nishant D Patel; Susan L Ullrich; Stuart D Russell; Ashish S Shah; John V Conte Journal: J Heart Lung Transplant Date: 2009-10-17 Impact factor: 10.247
Authors: Alexander Iribarne; Mark J Russo; Alan J Moskowitz; Deborah D Ascheim; Lawrence D Brown; Annetine C Gelijns Journal: Semin Thorac Cardiovasc Surg Date: 2009